Inventory of heavy peptide varieties, the 100 billion market is waiting to be fed
Polypeptides are a class of compounds composed of 2-100 amino acids linked by peptide bonds. From the beginning of the 20th century to the present, more than tens of thousands of polypeptides have been discovered from living organisms, involving hormones, cell growth, nerves, reproduction, immune regulation, tumor lesions and many other fields, and have a wide range of physiological activities. Its molecular size is between small molecule chemical drugs (MW<500) and macromolecular protein drugs (MW>10000), which balances the characteristics of chemical drugs and biological drugs.
● Compared with protein drugs such as monoclonal antibody drugs and recombinant protein drugs, peptide drugs have the advantages of simpler spatial structure, higher stability, lower or no immunogenicity, etc. Features of good curative effect;
● Compared with small-molecule drugs, peptide drugs have advantages in biological activity, specificity and solving complex diseases. At the same time, the production and preparation methods of peptide drugs are similar to small-molecule drugs, with controllable quality and easy structure. , low cost and so on.
Combining various advantages and characteristics, peptide drugs have been greatly increased in the market in recent years. From 2015 to 2019, the compound annual growth rate of the global peptide drug market was 8.2%; in 2019, the global peptide drug market size was about 29.4 billion US dollars, a year-on-year increase of 15.75%; it is estimated that in 2020, the global peptide drug market size will reach 31.5 billion US dollars (approximately RMB 212.4 billion).
Peptide drugs account for a small share of the total global pharmaceutical market, but their growth rate is high. The compound annual growth rate in the world is much higher than that of chemical drugs and biological products. The growth rate of the market size is about the overall growth rate of the global drug market size. 2 times.